. . World News – United States – Novavax Launches Phase 3 COVID Vaccine Trial With Plans, Jan.. 000 volunteers in U.. S.. . and Mexico

Novavax Inc. .
NVAX,
-2. 33%
said Monday it was starting a late-stage trial of its COVID-19 vaccine candidate with plans to last up to 30. 000 volunteers to enroll in about 115 locations in the U.. S.. . and Mexico. The study is supported by partners in Operation Warp Speed, the federal government’s program to rapidly develop vaccines and therapies, including the Department of Defense and the National Institute of Allergies and Infectious Diseases (NIAID), part of the National Institutes of Health is (NIH) and the Biomedical Advanced Research and Development Authority (BARDA), part of the U. . S.. . Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response. Barda will provide up to $ 1. 6 billion to fund the process under a Department of Defense agreement. The study is randomized, placebo-controlled and evaluates the effectiveness of the treatment known as NVX-CoV2373 in patients aged 18 years and over. Shares were a little higher on Monday, and up more than 3 in 2020 due to vaccine hopes. 000% growth.

Undefined shares of Myovant Sciences rose 20% in premarket trading Monday after parent company Sumitovant Biopharma announced that Myovant would join Pfizer Inc. . Undefined to jointly develop prostate cancer and women’s health treatment in one deal valued at up to $ 4. 2 billion upfront payments and potential milestone payments. Myovant will receive a $ 650 million upfront payment to develop Relugolix, a once-daily oral gonadotropin-releasing hormone receptor antagonist for oncology and women’s health in the United States. S.. . and Canada. Pfizer has exclusive rights to commercialize Relugolix in oncology outside of the United States. S.. . and Canada, excluding some Asian countries. Myovant is one of five companies under the Sumitovant umbrella. « Myovant and Pfizer will jointly develop and market ORGOVYX (TM) (Relugolix) for advanced prostate cancer and, if approved, Relugolix combination tablet (Relugolix 40 mg, estradiol 1). 0 mg and norethindrone acetate 0. 5 mg) in women’s health in the U. . S.. . and Canada, « the companies said in a joint statement. The U. S.. . The Food and Drug Administration approved Orgovyx on Dec.. approved. 18 for the treatment of advanced prostate cancer. Pfizer stocks were a little higher before going public, gaining 0. 4% in the year to date, while the undefined S&P 500 increased by 15%.

Novavax, Inc, Vaccine, NIH, Adjuvant, National Institute for Allergies and Infectious Diseases